We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Micap | LSE:MIC | London | Ordinary Share | GB0033274050 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.375 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.375 | GBX |
Micap (MIC) Share Charts1 Year Micap Chart |
|
1 Month Micap Chart |
Intraday Micap Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/11/2008 | 20:49 | Micap (food tech company) now floated | 663 |
| 26/9/2007 | 06:42 | MICAP's results out tomoro 26th sept...confirmed by company..3 bagger? | 7 |
| 07/9/2007 | 11:44 | MICAP IS SUCH A LOW CAP...ISSUES UPBEAT TRADING STAT! | 39 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 31/7/2008 17:09 by trixter Does this look like an extension/developmenAIMHO etc. |
Posted at 28/9/2007 07:10 by trixter Well, could have been a lot worse. Placing provides a good foundation going forward and there are glimmers on the agrochemicals work. The increasing involvement of Mapstone has to be good news. I take it all back! There is still the tantalising link up with MDX (or not). I'd have liked to have bought more at the riduculous opening price, but cannot get any and the price is now up a bit - but still can't buy on line and it's 1.40 - 1.40 LOL! It would also be good if PIs could get the placing price occasionally.... Might drop as HB feed into the market, unless they already have a home for these? Otherwise at least the issued shares will be very tightly held. IMO, DYOR, etc. |
Posted at 26/9/2007 19:13 by trixter Opti - I hope your name isn't misplaced. This was the mention of the UK in Nufarm's results relased yesterday. "Both France and Spain also increased sales and profit, however the UK business suffered from the withdrawal of a product registration and delays in the introduction of planned new products. These impacts occurred very late in the financial year and had a substantial negative impact on the UK results." Okay, Nufarm UK must have a few things on the go and this may: (i) mean nothing for Micap; (ii) mean the Micap programme has not gone well; (iii) the MICAP programme delayed (which we knew - they wanted another 6 months) but new products will come; (iv) other programmes not gone well - they need MICAP; (v) something else entirely. All speculation, AIMO, DYOR, etc. but thought I would at least share this morsel - there's not many crumbs for us to go on. Could be nothing, could be bad, could be good. Let's hope they tell us somethings soon! The full release from Nufarm can be found on their website - see above. |
Posted at 26/9/2007 06:42 by trixter Perhaps they are waiting for Mr Mapstone to get back from a round the world cruise or he's too pre-occupied fixing Hill Station...! Let's hope MIC are not another HLL! |
Posted at 18/9/2007 09:45 by trixter On the iii MIC board today there is speculation about the possible link between MIC and MDX (BPRG)."Quite possible with the Meldex (Bioprogress) tie up. Its old (2004) but these things take time. I actually believe the results will show a marked improvement." Anyone know the latest on this? MDX release results on 25/9. Wonder if MIC will release the same day? The chances narrow with every day that passes... I hold MIC. IMO, DYOR etc... |
Posted at 06/4/2005 06:07 by pomp circumstance At last!!!!MICAP PLC 06 April 2005 6th April 2005 SKYEPHARMA NOMINATES PRODUCTS FURTHER TO EXERCISE OF OPTION AND TRADING UPDATE Micap plc (LSE: MIC), the technology licensing company specialising in the microencapsulation of active ingredients in yeast cells, today announces that SkyePharma plc (LSE: SKP, Nasdaq: SKYE) will incorporate Micap's yeast-based delivery system in its ongoing development of a further nine (9) pharmaceutical products. This announcement completes SkyePharma's current option agreement with Micap. In March 2004, SkyePharma exercised an option to acquire an exclusive licence to use Micap's patented microencapsulation technology. This allowed SkyePharma to use Micap's technology for the delivery of hydrophobic drugs in up to ten nominated pharmaceutical products ('Option Products') to be selected by SkyePharma and in August 2004 the first Option Product was nominated. SkyePharma has, since the first Option Product was nominated, been evaluating a number of other potential Option Products, using its experience of drug delivery technologies to identify those compounds most suitable for the Micap technology and with the greatest market opportunity and has now nominated the remaining nine (9) Option Products. Whilst the identity of these products cannot be disclosed for reasons of commercial confidentiality, they are all oral doseage forms and include a combination of proprietary and generic compounds. Under the terms of the March 2004 agreement, royalties will be payable by SkyePharma to Micap on sales made of, or licences granted on, any Option Product. SkyePharma will also make milestone payments on the successful completion of Phase II and Phase III clinical trials and also on the commercial launch of the first Option Product. Micap will now carry out an optimisation program on the encapsulated compounds and SkyePharma will undertake formulation and stability studies with a view to commencement of further pre-clinical trials. Micap continues to be in discussions with a number of partners regarding evaluation, development and licensing deals and hopes to be in a position to inform shareholders of further progress on these negotiations soon. These discussions have been progressing well, however, in some cases they have taken longer than expected to conclude and whilst costs remain in line with management's expectations, certain access and option fees anticipated to be received in the financial year to 31 March 2005 will now fall due in the new financial year. The Board is pleased with the significant progress in both the quality and number of Micap's partnerships and look forward to positive developments in the coming months. Michael Brennand, Chief Executive of Micap, said: 'The nomination by SkyePharma of their remaining Option Products is a significant milestone for Micap. Not only are we moving to the next stage of development with a world leading drug-delivery company, but the conclusion of the Option agreement with SkyePharma allows us to actively market our patented encapsulation system to other companies within the pharmaceutical market. We are particularly excited about our opportunity in relation to topical skin applications of products, where we have recently experienced highly positive results in laboratory trials.' For further information please contact: Contact: Micap plc +44 (0)1925 664200 Michael Brennand, CEO +44 (0)7966 341801 Michael Norris, CFO +44 (0)7966 341802 Binns & C PR +44 (0)20 7786 9600 Tarquin Edwards/Chris Steele 07879 458 364 / 07979 604 687 |
Posted at 23/2/2005 07:03 by pomp circumstance RNS Number:9141IMICAP PLC 23 February 2005 For release 23 February 2005 Micap plc ("Micap" or "the Company") Acquisition of Rendel & Scherer GbR ("R&S") for up to Euro1.0 million Micap plc, the UK microencapsulation specialist, announces the acquisition of Rendel & Scherer GbR, a company with a strong reputation as a provider of innovative microencapsulation solutions, originally to the food industry, and more recently, a growing expertise within the Nutriceutical and Cosmeceutical markets. The acquisition is expected to make a positive contribution to Group profitability in its first year. Michael Brennand, CEO of Micap, commented: "This is a very exciting acquisition, which will bring new skills and intellectual property into the Group across a wide range of microencapsulation technologies, and will help in establishing Micap as the clear industry leader for industrial companies facing microencapsulation challenges. We shall look to both R&S and Applied Analysis to assist in our drive to commercialisation in the natural healthcare market, where the opportunities for new product developments utilising microencapsulation are significant". Based in Bremerhaven, Germany, and founded in 2002, R&S is currently working on a number of revenue generating projects, including long term royalty and contractual arrangements with, inter alia, a leading German flavour house and a supplier of yeast/cultures to the bakery and wine industry. R&S has also recently supplied essential oils encapsulated in a novel delivery system to a cosmetics partner, for use in a newly launched product. In addition R&S is a partner in a European Network project called Flow-cap, where it is part of a consortium of organisations developing a system to protect live probiotic bacteria during processing. This system has applications in both the cheese and candy industries. The acquisition by Micap of the entire issued and potentially issuable share capital of R&S, is for an initial consideration of Euro 0.25 million, with a further Euro 0.75 million of deferred consideration subject to performance (see footnote). The consideration is payable in a mixture of cash and ordinary shares in Micap plc. A new company, Micap GmbH, has been created to acquire the business of R&S, which is an established partnership between Mr Jorg Rendel and Mr Carlo Scherer, who will both remain as directors of Micap GmbH. Jorg Rendel, Director of R&S added: "Carlo and I are delighted to be joining the Micap group, and we look forward to the opportunity of utilising Micap's exciting technologies and bringing our know-how, experience and skills in microencapsulation solutions to a wide range of new challenges". - Ends - For further information: Micap plc Tel: +44 (0) 1925 664 200 Mike Brennand, Chief Executive +44 (0) 7966 341801 Michael Norris, Finance Director +44 (0) 7966 341802 Binns & Co Tel: +44 (0) 20 7786 9600 Chris Steele/Tarquin Edwards +44 (0) 7979 604 687 / +44 (0) 7879 458 364 Footnote The deferred consideration of up to Euro 750,000 is payable to the Vendors (Messrs. Rendel and Scherer) subject to achievement of turnover targets as follows: Calendar year Turnover target Consideration in cash Consideration in shares 2005 Euro 500,000 Euro 100,000 Euro 100,000 Euro 750,000 No further payment Further Euro 50,000 2006 Euro 1,300,000 Euro 150,000 Euro 150,000 Euro 2,000,000 No further payment Further Euro 150,000 2007 Euro 1,300,000 Euro 25,000 Euro 25,000 In assessing the number of shares in the Company to be issued to the Vendors pursuant to the deferred consideration referred to above, the value attributed to each share shall be the average of the middle market quotations of shares in the Company as derived from the AIM market daily list for the thirty days prior to the date on which the payments become due. The company can, at its sole discretion, opt to pay the share element of the deferred consideration in cash. Notes to editors: About Micap Micap listed on AIM in August 2003 and is a UK technology licensing company specialising in the microencapsulation of active ingredients within yeast cells. For further details visit www.micap.co.uk Microencapsulation is a process whereby tiny droplets of liquid or particles of solid material are coated with a continuous film of polymeric material. Microcapsules have several benefits, including conversion of liquids to solids; separating reactive compounds; protecting substances against environmental factors; and improving the material handling properties. Micap's unique proprietary technology involves using killed yeast cells as natural capsules to protect the active ingredient. Yeast encapsulation can protect active ingredients against high temperatures, the effects of the sun, pressure and degradation through exposure to the air. The natural affinity of yeast cells for mucous membranes can also be exploited for targeted drug delivery. This information is provided by RNS The company news service from the London Stock Exchange END ACQTTMRTMMATBIA |
Posted at 20/10/2004 06:42 by m.t.glass "...Discussions are currently underway with a major multinational..." MICAP PLC 20 October 2004 Micap plc 20th October 2004 Micap plc announces positive results of a recent study on use of Micap encapsulated fungicides to improve control of fungal damage to cereal crops. Micap plc ('Micap', LSE: MIC) today announces new business opportunities in the area of agrochemicals. Further to the recently-reported success in the evaluation of Micap technology for herbicides, promising new results have now been obtained in fungicide applications. Micap has funded laboratory trials at the University of Nottingham comparing the performance of a commercial fungicide formulation with a formulation based on Micap technology. The target for the study was the ear blight fungus Fusarium, which represents a significant commercial threat to cereal farmers. The outcome of the study showed that a standard Micap formulation performed well compared to a commercial product for stem based disease control. Additionally, in mature plants, when wheat ears were infected, the Micap formulation of the fungicide tebuconazole outperformed the commercial product, resulting in an increased grain yield. In addition, subsequent studies have demonstrated a substantial reduction in the levels of Fusarium mycotoxin present in the grain of Micap-treated plants. This is a likely reflection of the benefit of sustained release of the active ingredient. The use of the Micap encapsulation technology for the delivery of fungicides offers the potential to control mycotoxin contamination of grain to below 0.75ppm, the target level currently under review by the European Union. Michael Brennand, Chief Executive of Micap, said: 'We are delighted at these encouraging study results and look forward to the continued development of fungicidal applications.' Dr. Steve Rossall, senior lecturer in plant pathology at Nottingham University, commented: 'The results produced by the Micap technology in the Fusarium study were very promising, particularly since the formulation of the Micap product had not been optimised.' Discussions are currently underway with a major multinational to carry out field trials incorporating the Micap formulation of tebuconazole used in the study. Ongoing studies include the evaluation of Micap formulations of a number of azole fungicides against their commercial equivalents, whilst trials of seed dressing applications are currently at the planning stage. Contact: Micap plc 01925 664200 Michael Brennand, CEO 07966 341801 Michael Norris, Finance Director 07966 341802 Gavin Anderson & Company 020 7554 1400 Janine Brewis About Micap Micap listed on AIM in August 2003 and is a UK technology licensing company specialising in the micro encapsulation of active ingredients within yeast cells. For further details visit www.micap.co.uk . Micro encapsulation is a process whereby tiny droplets of liquid or particles of solid material are coated with a continuous film of polymeric material. Microcapsules have several benefits, including conversion of liquids to solids; separating reactive compounds; protecting substances against environmental factors; and improving the material handling properties. Micap's unique proprietary technology involves using killed yeast cells as natural capsules to protect the active ingredient. Yeast encapsulation can protect active ingredients against high temperatures, the effects of the sun, pressure and degradation through exposure to the air. The natural affinity of yeast cells for mucous membranes can also be exploited for targeted drug delivery. About Fusarium blight The global market for agrochemicals is around $30bn and is split into three main sectors: herbicides, fungicides and insecticides. Fusarium is a stem-based pathogen of cereals which primarily affects the ears, causing reduced yield and importantly a contamination of the grain with mycotoxins, which are potentially harmful to people. Fusarium Ear Blight infection was estimated to cause a loss in excess of $2.5bn to farmers in the US between 1998-2000 (Ngenje et al, Oct 2001). Mycotoxins Mycotoxins are toxic chemicals produced by moulds growing on food commodities or animal feedstuffs. In order to protect public health, they are subject to government regulation in most countries. This information is provided by RNS The company news service from the London Stock Exchange |
Posted at 25/8/2004 06:37 by m.t.glass Beckaroo - more on that catheter grant:RNS Number:2801C MICAP PLC 25 August 2004 25 August 2004 Micap plc ("Micap" or "the Company") Micap to benefit from UK Government's Nanotechnology funding for research into antimicrobial technology for urinary catheters Micap, the UK technology licensing company specialising in the micro encapsulation of active ingredients within yeast cells, today announces that it has been awarded funding from the UK Government's Micro and Nanotechnology manufacturing initiative to carry out a development project investigating the prevention of microbial colonisation of polyurethane-based catheters. The total project value is approximately #260,000, and the new grants will cover 50% of this cost. The funding is for a two year project to develop the use of antimicrobial technology from Manchester Metropolitan University, polyurethane catheter technology from Biomer Technologies Ltd, and Micap PLC's yeast microencapsulation technology. The development will focus on nosocomial infections that represent an enormous financial burden on healthcare systems in terms of extended hospital stay and patient care. Many of these infections are catheter related and bacteria are becoming increasingly resistant to most commonly used antibiotics and antiseptics. For example, each year more than 1 million patients in U.S. acute-care hospitals and extended-care facilities acquire such an infection (Maki & Tambyah, Emerging Infectious Diseases, Mar-Apr 2001). * This project will employ Micap's novel yeast based micro-encapsulation technology, which is able to protect volatile antimicrobials through high temperature polymer production and to control and target release of the antimicrobial agent during the catheter lifetime. * A combination of commercially available biocides and antibacterial natural plant oils such as tea tree oil will be used to overcome problems of bacterial resistance. Dr Gordon Nelson, Technical Director at Micap, said: "We are delighted to receive the award from the DTI. A successful outcome could help the NHS to save millions of pounds each year by reducing antibiotic use, in addition to the potential for freeing up hospital beds. The DTI support helps innovative companies, such as Micap and Biomer, to turn their ideas into reality, creating jobs and prosperity for the companies and the UK." - Ends - For further information: Micap plc Tel: +44 (0)1925 664200 Dr Gordon Nelson, Technical Director +44 (0)7966 341814 Michael Norris, Finance Director +44 (0)7966 341802 Media enquiries: Gavin Anderson Liz Morley/Janine Brewis Tel: +44 (0)20 7554 1400 Notes to editors: "Nosocomial" - a secondary disorder associated with being treated in a hospital but unrelated to the patient's primary condition. The DTI's Micro and Nanotechnology Manufacturing Initiative. On 2 July 2003, the UK Science and Innovation Minister, Lord Sainsbury, announced a cash injection of #90 million over the next six years to help industry harness the commercial opportunities offered by Micro and Nanotechnologies (MNT). This #90 million will be spent on collaborative R&D and a new network of Micro and Nanotechnology facilities, and forms the first step of developing and implementing a new Technology Strategy. This will help business build on the UK's excellent scientific track record in these small-scale sciences and win a share of the developing market. The new investment is also securing additional industry and regional spending anticipated to exceed #200 million to provide a boost to future advanced manufacturing in the UK. Within this Initiative, DTI has allocated #50 million for grants under an Applied Research Programme of collaborative R&D leading to significant economic impact for the UK. #40 million has also been allocated towards facilities development for a UK Micro and Nanotechnology (MNT) Network. More information relating to the MNT Network can be found at: www.microandnanotech Micap plc Micap plc is a technology development, production and licensing company that micro encapsulates active ingredients ('actives') in single celled organisms, in particular yeast. These organisms can be used to protect and deliver 'actives' for the flavouring, agrochemical and pharmaceutical industries. The natural cell wall of the yeast protects the active ingredient against evaporation, pressure, oxidation and light, allowing: * Highly concentrated, heat resistant flavours * Targeted drug delivery and delivery of drugs which alone would be broken down in the stomach before taking effect * Natural enhancement of cosmetic ingredients Biomer Technologies Biomer Technology Ltd (BTL), based in the UK, exploits intellectual property associated with the development of novel polymers with attractive properties for product applications in medical device applications. BTL's enabling technologies are focused on developing materials and solutions for the global healthcare market including, cardiovascular monitoring, drug eluting materials, and other interventional applications. The BTL polymer technologies include highly flexible medical grade polyurethanes (ZytarTM), which have already been approved for use in humans, and a revolutionary biocompatible coating system, which is under development for drug delivery, tissue engineering and biocompatible coating applications. Catheters Market The US market for Antimicrobial Catheters in 2002 was $98.7 Million rising to approximately $206 Million in 2006 (Frost and Sullivan Report - Antimicrobial catheters market: revenue forecasts 1999-2009). This information is provided by RNS The company news service from the London Stock Exchange END RESILFFDTIISFIS |
Posted at 17/8/2004 06:11 by bigboony MICAP PLC17 August 2004 17 August, 2004 SKYEPHARMA EXERCISES OPTION UNDER AGREEMENT WITH MICAP Micap plc (LSE: MIC), the technology licensing company specialising in the microencapsulation of active ingredients in yeast cells, today announces that SkyePharma plc (LSE: SKP, Nasdaq: SKYE) has decided to exercise its option to select for further development a number of pharmaceutical products that incorporate Micap's yeast-based delivery system. In March 2004, SkyePharma exercised an option to acquire an exclusive licence to use Micap's patented microencapsulation technology. This allows SkyePharma to use Micap's technology for the delivery of hydrophobic drugs in up to ten nominated pharmaceutical products ('Option Products') to be selected by SkyePharma. SkyePharma has subsequently been evaluating a number of potential Option Products and is now in a position to nominate the first Option Product. The identity of this product has not been disclosed for reasons of commercial confidentiality. SkyePharma will continue to review additional product opportunities, and expects to make further nominations prior to the expiry of the Option Period. Under the terms of the March agreement, ongoing royalties will be payable by SkyePharma to Micap on sales made, or licences of, any Option Product. SkyePharma will also make milestone payments on the first successful completion of Phase II and Phase III clinical trials and also on the first commercial launch of an Option Product. Michael Brennand, Chief Executive of Micap, said: 'The commitment shown by SkyePharma is a major validation of the potential applications of our microencapsulation technology in the pharmaceutical area. We look forward to progressing the relationship through clinical trials and product launches.' Michael Ashton, Chief Executive of SkyePharma, said: 'We continue to be pleased with our relationship with Micap. In January 2003, we agreed to evaluate the application of the Micap microencapsulation technology to the delivery of hydrophobic drugs. Following pre-clinical evaluation of the Micap technology in both oral and topical drug delivery applications, we decided to exercise our option in March this year. We are now able to report that we have selected the first Option Product for further development. We will continue to evaluate other candidate Option Products, which we must nominate by the end of March 2005. The Micap technology further expands our growing range of drug delivery options.' For further information please contact: Contact: Micap plc +44 (0)1925 664200 Michael Brennand, CEO +44 (0)7966 341801 Gavin Anderson & Company (For Micap) +44 (0)20 7554 1400 Liz Morley/Janine Brewis/Tom Siveyer SkyePharma plc +44 (0)20 7491 1777 Michael Ashton, CEO Peter Laing, Director of Corporate Communications +44 (0)20 7491 5124 Notes for editors: About Micap Micap is a UK technology licensing company specialising in the microencapsulation of active ingredients within yeast cells. For further details visit www.micap.co.uk . About SkyePharma SkyePharma develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now ten approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www.skyepharma.com . About microencapsulation Microencapsulation is a process whereby tiny droplets of liquid or particles of solid material are coated with a continuous film of polymeric material. Microcapsules have several benefits, including conversion of liquids to solids; separating reactive compounds; protecting substances against environmental factors; and improving the material handling properties. Micap's unique proprietary technology involves using killed yeast cells as natural capsules to protect the active ingredient. Yeast encapsulation can protect active ingredients against high temperatures, the effects of the sun, pressure and degradation through exposure to the air. The natural affinity of yeast cells for mucous membranes can also be exploited for targeted drug delivery. About hydrophobic drugs Certain pharmaceuticals dissolve readily in oils or organic solvents but are wholly or partially insoluble in water. These hydrophobic drugs pose particular delivery problems since, in order to be properly absorbed by the body, nearly all drugs need to dissolve in water. This information is provided by RNS The company news service from the London Stock Exchange |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
